logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ 50 Mg/day

Pfizer Inc. (PFE: Quote) announced new data on PRISTIQ (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder, or MDD, in adults, including a long-term relapse prevention study.

According to the company, these new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the treatment of MDD. Lastly, new data also provide information regarding the discontinuation of PRISTIQ 50 mg/day for the treatment of adults with MDD.

These new PRISTIQ 50 mg/day data focus on key factors - efficacy, safety, long-term use and discontinuation - that clinicians often consider when assessing antidepressants for the treatment of MDD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Online retail giant Amazon.com Inc. (AMZN) is reportedly in talks to buy luxury online fashion retailer Net-a-Porter. The news of acquisition was first reported by Women's Wear Daily, which said the deal would be completed for about 2 billion euros, indicating the biggest acquisition yet by Amazon.... Tim Cook, the CEO of tech giant Apple Inc., in an interview said he intends to give away all his wealth to charity. Cook, in an interview to Fortune, said he plans to donate all his wealth to philanthropic projects after paying for his 10-year old nephew's college education. According to Fortune,... Is it a 'personal life crisis' that led the Germanwings' co-pilot Andreas Lubitz to deliberately lowering the plane carrying 149 people to French Alps mountain? Police is investigating to find evidences to prove this suggestion.
comments powered by Disqus
RELATED NEWS
Trade PFE now with 
Follow RTT